SMRTmeds is positioned to penetrate a $77B vaccinology market, growing at 12% CAGR. With an initial focus on improving the NHS and other European healthcare systems' vaccination programmes, we offer:
Approximately 30% cost savings for public health systems via optimized dosing
Reducción de 200 millones de euros en costes de ensayos farmacéuticos impulsados por IA
Scalable revenue models estimated to: B2B subscriptions ($500/month), licensing ($1M/year), and pay-per-test ($5)
PIONEERING BIOTECHNOLOGY IN OXFORD
Current Traction
● Winners of the All Innovate Competition at the University of Oxford
● Pre-seed target: $500K for regulatory compliance and pilot scaling.
● Partnerships in progress with key healthcare institutions.
Market Opportunity
● RSV/HPV vaccines: $4.5–7.5B market by 2027 (IQVIA report).
● Global demand: 16B vaccine doses administered annually (WHO).
